Overview

Pharmacokinetics Study of Asciminib in Subjects With Impaired Renal Function Compared to Matched Healthy Volunteers

Status:
Completed
Trial end date:
2019-04-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the pharmacokinetics (PK) and safety profile of asciminib following a single oral dose in adult subjects with renal impairment compared to a matched group of healthy subjects with normal renal function. The results will determine whether or not a dose adjustment should be recommended when treating patients with asciminib who have impaired renal function.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals